Lion TCR Stock

Lion TCR is a clinical-stage biotechnology company.

Sign up today and learn more about Lion TCR Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Lion TCR Stock

They are a clinical-stage biotechnology company that develops TCR-T cell therapy for cancers and life-threatening infectious diseases in Asia. For the past decade, they have accumulated expertise covering the entire product development process, ranging from basic research, T cell engineering and development, and preclinical/clinical assessment. Led by industry and academic experts from their base in Singapore, they are dedicated to the commercialization and continued development of their immunotherapy products.

Funding History

May 2018$20.0M
June 2023$300M



Stephen Lim

Co-Founder, Chairman & CEO

Lietao Li

Co Founder

Antonio Bertoletti


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: